BOMACILLIN LA PENICILLIN INJECTION

Main information

  • Trade name:
  • BOMACILLIN LA PENICILLIN INJECTION
  • Class:
  • Veterinary Medicine
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • BOMACILLIN LA PENICILLIN INJECTION
    Australia
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • CAT | CATTLE | DOG | HORSE | PIGS | SHEEP | BEEF | BITCH | BOAR | BOS INDICUS | BOS TAURUS | BOVINE | BUFFALO | BULL | BULLOCK |
  • Therapeutic area:
  • ANTIBIOTIC & RELATED
  • Therapeutic indications:
  • BACTERIAL INFECTION | AMOXYCILLIN SENSITIVE BACTERIA | ASSOCIATED WITH VIRAL DISEASE | GRAM NEGATIVE ORGANISMS | GRAM POSITIVE ORGANISMS | POST PARTURIENT BACTERIAL INFE | PRIMARY BACTERIAL INFECTION | SULFADIAZINE SENSITIVE BACTERI | TRIMETHOPRIM SENSITIVE BACTERI | TYLOSIN SENSITIVE BACTERIA

Other information

Status

  • Source:
  • Australian Pesticides and Veterinary Medicines Authority (APVMA)
  • Authorization status:
  • Registered
  • Authorization number:
  • 36008
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Complying to 91/155/EC, 93/112/EC

Material SafetyData Sheet

Bomacillin LA

Revision date :7 June, 2000 Printing Date:21 August, 2002 Page1 of 6

1.CHEMICALPRODUCTAND COMPANY IDENTIFICATION

Product Name Bomacillin LA

Supplier Norbrook Laboratories Ltd,

Station Works,Newry,

Co.Down, BT35 6JP,

N.Ireland.

Telephone No. +44 (0) 28 3026 4435

FaxNo. +44 (0) 28 3026 1721

E-Mail: enquiries@norbrook.co.uk.

EmergencyTelephone +44 (0) 28 3026 4435

2. COMPOSITION / INFORMATION ON COMPONENTS

Substance/Preparation:Preparation

ActiveIngredients : ProcainePenicillin

Benzathine Penicillin

Description : Antibiotic

ChemicalFamily : Penicillin

3. HAZARDS IDENTIFICATION

Physical and Chemical Hazards : NotclassifiedasdangerousunderEECDirectives

67/548/EEC, 88/379/EEC or 99/45/EC

Environmental Hazards : None known

AdverseHuman Health Effects : Penicillins may cause sensitization following

injection, inhalation, ingestion or skin contact.

Sensitivityofpenicillin mayleadtocrosssensitivity

to cephalosporins. Allergicreactionstothese

substances are occasionallyserious. Medicaladvice

should be sought quickly.

Complying to 91/155/EC, 93/112/EC

Material SafetyData Sheet

Bomacillin LA

Revision date :7 June, 2000 Printing Date:21 August, 2002 Page2 of 6

4. FIRST AID MEASURES

Inhalation : Removetofreshair.Ifanysignsorsymptomsoccurorpersistseekmedical

advice

SkinContact: Wash thoroughlywith soap and water. Remove contaminated clothingand

wash before reuse.

Eyes Contact: Immediatelyflush eyes with copious amounts of water for at least 15

minutes. Ifirritation persists, seek medical attention.

Ingestion : Do not induce vomiting.Seek medical attention.

5. FIREFIGHTINGMEASURES

Extinguishingmedia: Usecarbon dioxide, drychemical or alcohol-resistant foam spray

extinguishers.Use water sprayto cool fire-exposed containers. A

fine water mist maybe used to smother or to disperse vapours.

Fire and explosion hazards: None.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions : Provide good ventilation. Prevent skin and eye contact.

Environmental Precautions: Keep awayfrom drains, surface-water, ground-water and soil.

Method for Clean-up :Absorbsmallspillsonspillpillows,sand,sawdustorothersuitable

absorbingmaterial.

7. HANDLINGAND STORAGE

Handling : Avoidcontactwitheyes,skinorclothing.Donotbreathevapoursormist.

Do not ingest. Do not smoke or eat while handlingtheproduct.Wash

thoroughlyafter handling.The containers should be stored in theiroriginal

boxes when not in use.

Storage : Storeinclosedcontainersinacool,dry,well-ventilatedarea,below25 °

C

and awayfrom oxidisers, heat, sparks and open flame. Protect containers

from physical damageand light.

Complying to 91/155/EC, 93/112/EC

Material SafetyData Sheet

Bomacillin LA

Revision date :7 June, 2000 Printing Date:21 August, 2002 Page3 of 6

Keep container closed when notinuse. Do nottransfercontentsto

unlabelled containers. Use onlywith adequate ventilation. Keep out ofreach

of children.

8. EXPOSURECONTROLS/ PERSONALPROTECTION

Component - Occupational Exposure Standard

Procaine Penicillin Not Established

Benzathine Penicillin Not Established

For pure procaine penicillin :

LD50 ( Oral, mouse ) 2300 mg/kg

LD50 ( Oral, rat ) >

5000 mg/kg

For pure benzathine penicillin

LD50 ( Oral, mouse ) 2000 mg/kg

Protective Equipment : Wearvinylorrubbergloves,awaterproofbib-apronandsuitable

eye protection when applyingthe product.

9. PHYSICALAND CHEMICALPROPERTIES

Form : Aqueous suspension

Colour: White

Odour : None.

10. STABILITY AND REACTIVITY

Stability : Stable under normal temperatures and pressures.

Conditions to avoid : None known

Materials to avoid : None known

Complying to 91/155/EC, 93/112/EC

Material SafetyData Sheet

Bomacillin LA

Revision date :7 June, 2000 Printing Date:21 August, 2002 Page4 of 6

11. TOXICOLOGICAL INFORMATION

Exposure Effects ( Acute )

EyeContact: Directcontactof the aqueous suspension witheyes can cause

irritation.

SkinContact: Prolongedorrepeatedcontactwith Bomacillin LAmaycause

irritation and/or dryingand crackingof the skin.

Inhalation : None known.

Ingestion : OraltoxicityoftheBomacillin LAsuspension is low.

Ifsymptomsdevelopfollowingexposure,such as a skin rash, seek medical advice, and

show the doctor this Product SafetyData Sheet. Swellingof the face, lips oreyesand/or

difficultywith breathingare more serious symptoms and require urgentmedical attention.

Exposure Effects ( Chronic )

Unknown for the product mixture. When this product isused

accordingtothedirections,prolonged exposure of man isnot

expected. Both its mutagenicityand its teratogenicityarenot

known.

12. ECOLOGICAL INFORMATION

Dataon theecologicalimplications forBomacillin LAis not yet available.

13. DISPOSAL CONSIDERATIONS

Product/Residues : Donotdischargetheproductmaterialintosurfaceorwaste

water. For disposal, use anincineratorlicencedforchemical

waste.

Package : Disposeofwastecontainersusingregulardisposalmethods

inaccordance withlocaland nationalenvironmental

regulations.

Complying to 91/155/EC, 93/112/EC

Material SafetyData Sheet

Bomacillin LA

Revision date :7 June, 2000 Printing Date:21 August, 2002 Page5 of 6

14. TRANSPORT INFORMATION

Land Transport

ADR No., RID No., UN No., : Not applicable

Sea Transport

IMO / IMDG code, UN No. : Not applicable

Air Transport

IATA / ICAO Class, Un No. : Not applicable

15. REGULATORY INFORMATION

LabellingInformation : None

Safetyphrases: S2 Keep outof reach of children

S7 Keep container tightly closed

16. OTHER INFORMATION

ForAnimal Treatment Only

Updated PSDS Creation Date : 07/06/00

Suppliers datasheets and various chemicals and pharmaceuticals databases were used tocompilethis

sheet.

The information contained inthisPSDSisbelieved tobe accurateandrepresentsthebestinformation

available at the time of preparation. However Norbrook Laboratories Limited makes nowarranty,

expressorimplied,withrespectto suchinformation and assumes no liabilityresultingfrom its use.

Users should make their own investigations to determine the suitabilityoftheinformationfortheir

particular purposes, and Norbrook Laboratories Limited will not be heldliableforanydamage

resultingfrom the handlingof or contact with the above product.

There are no safety alerts related to this product.

21-9-2018

Scientific guideline:  Reflection paper on the use of aminopenicillins and their beta-lactamase inhibitor combinations in animals in the European Union: development of resistance and impact on human and animal health, draft: consultation open

Scientific guideline: Reflection paper on the use of aminopenicillins and their beta-lactamase inhibitor combinations in animals in the European Union: development of resistance and impact on human and animal health, draft: consultation open

The objective of this document is to review available information on the use of aminopenicillins and their beta-lactamase inhibitor combinations in veterinary medicines in the EU, their effect on the emergence of antimicrobial resistance (AMR) and the potential impact of resistance on human and animal health. The document provides information for the risk profiling, as recommended by the Antimicrobial Advice ad hoc Expert Group (AMEG) of the EMA.

Europe - EMA - European Medicines Agency